Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease

Kotz, Daniel; Viechtbauer, Wolfgang; Simpson, Colin R; Schayck, Onno C. P. van; West, Robert A.; Sheikh, Aziz

doi:10.1136/thoraxjnl-2017-210067

Cited by 19 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study of 14,350 smokers with COPD, varenicline reduced the risk of heart failure and depression by 44% (hazard ratio [HR], 0.56; 95% CI, 0.34–0.92) and 27% (HR, 0.73; 95% CI, 0.61–0.86), respectively18.…”

Section: Smoking Cessation Treatment For Specific Populationsmentioning

confidence: 99%

Smoking Cessation Strategies Targeting Specific Populations

Chun

2019

Tuberc Respir Dis

View full text Add to dashboard Cite

Quitting smoking helps smokers maintain their health and extend their lifespan by 10 or more years. Treatment strategies for smoking cessation should be tailored to individual smokers with special needs based on their specific circumstances. It is recommended that pregnant women adopt smoking cessation through counseling and behavioral interventions because the safety of medications has yet to be established. Counseling is the main strategy for smoking cessation in adolescents and nicotine replacement therapy can be used with caution in individuals with serious nicotine dependence. It is important for smokers with psychiatric diseases to quit smoking following accurate assessment of their depression status. Nicotine replacement therapy, varenicline, and bupropion can be used for smoking cessation in smokers with psychiatric disorders. The incidence of cardiovascular disease decreased according to the smoking status and the duration of smoking cessation. In smokers with chronic obstructive pulmonary disease (COPD) who used a combination of counseling and pharmacotherapy the quitting rate was more than twice as high as subjects who used behavioral interventions alone. Varenicline can be used as the most effective anti-smoking drug by most smokers including those with psychiatric disorders, cardiovascular disease, and COPD.

show abstract

Section: Smoking Cessation Treatment For Specific Populationsmentioning

confidence: 99%

Smoking Cessation Strategies Targeting Specific Populations

Chun

2019

Tuberc Respir Dis

View full text Add to dashboard Cite

show abstract

“…There have been only four RCTs, involving a collective total of 1,266 subjects, showing that varenicline is effective even at doses lower than those recommended for the general smoking population (RR = 2.08; 95% CI: 1.56-2.78) 33 . A retrospective study of more than 14,000 patients diagnosed with COPD, with or without cardiovascular or psychiatric comorbidities, showed that, in comparison with the use of NRT, the use of bupropion or varenicline did not increase the risk of cardiovascular or neuropsychiatric events within the first six months of treatment 41 …”

Section: Pharmacological Approachmentioning

confidence: 99%

Update on the approach to smoking in patients with respiratory diseases

et al. 2019

View full text Add to dashboard Cite

Smoking is the leading cause of respiratory disease (RD). The harmful effects of smoking on the respiratory system begin in utero and influence immune responses throughout childhood and adult life. In comparison with “healthy” smokers, smokers with RD have peculiarities that can impede smoking cessation, such as a higher level of nicotine dependence; nicotine withdrawal; higher levels of exhaled carbon monoxide; low motivation and low self-efficacy; greater concern about weight gain; and a high prevalence of anxiety and depression. In addition, they require more intensive, prolonged treatment. It is always necessary to educate such individuals about the fact that quitting smoking is the only measure that will reduce the progression of RD and improve their quality of life, regardless of the duration and severity of the disease. Physicians should always offer smoking cessation treatment. Outpatient or inpatient smoking cessation treatment should be multidisciplinary, based on behavioral interventions and pharmacotherapy. It will thus be more effective and cost-effective, doubling the chances of success.

show abstract

“…During smoking cessation treatment, the use of a nicotine replacement therapy for a sufficient period of time may help to reduce depressive symptoms (16). The efficacy of varenicline, nicotine patches, and bupropion in terms of the rate at which smokers successfully quit smoking (17) and the frequency of adverse psychiatric reactions, such as depression and self-harm (18,19), do not differ to a statistically significant extent. The frequency of smoking cessation interventions must be increased by more frequent clinic visits, longer counseling sessions, or repeating treatment.…”

Section: Smokers With Psychiatric Disordersmentioning

confidence: 99%

Support for Patients Who Have Difficulty Quitting Smoking: A Review

et al. 2019

View full text Add to dashboard Cite

Smoking cessation plays a crucial role in reducing preventable morbidity and mortality. However, some smokers find smoking cessation difficult, despite receiving treatment. This includes heavy smokers with chronic obstructive pulmonary disease, smokers with a psychiatric disorder, and female and underage smokers. This review article describes smoking cessation approaches for patients who find it difficult to quit smoking.

show abstract

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease

Abstract: In smokers with COPD, varenicline and bupropion do not appear to be associated with an increased risk of cardiovascular events, depression or self-harm in comparison with NRT.

Cited by 19 publications

References 23 publications

Smoking Cessation Strategies Targeting Specific Populations

Smoking Cessation Strategies Targeting Specific Populations

Update on the approach to smoking in patients with respiratory diseases

Support for Patients Who Have Difficulty Quitting Smoking: A Review

Contact Info

Product

Resources

About